nominally significantp = 0.0004
However, several lines of evidence point to an effect of the lower dose on exercise endurance: (i) tiotropium/olodaterol 2.5/5 μg significantly improved EET during CWRCE compared with placebo in both MORACTO ® studies [26.5% ( p < 0.0001) and 12.1% ( p = 0.0003)]; (ii) there was a nominally significant improvement in EET during CWRCE after 6 weeks (22.1%, nominal p = 0.0004) in the present study; (iii) in post hoc analysis, change from baseline in EET during CWRCE after 6 and 12 weeks was nominally significant.